AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 75 filers reported holding AVADEL PHARMACEUTICALS PLC in Q2 2018. The put-call ratio across all filers is 1.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $7,769,000 | -39.8% | 1,029,012 | -66.8% | 1.04% | -56.4% |
| Q3 2019 | $12,907,000 | +43.9% | 3,102,673 | 0.0% | 2.39% | +22.3% |
| Q2 2019 | $8,967,000 | +100.7% | 3,102,673 | 0.0% | 1.95% | +111.4% |
| Q1 2019 | $4,468,000 | -44.2% | 3,102,673 | 0.0% | 0.92% | -12.3% |
| Q4 2018 | $8,005,000 | -34.7% | 3,102,673 | +11.1% | 1.05% | -41.6% |
| Q3 2018 | $12,260,000 | -26.6% | 2,792,773 | +2.5% | 1.80% | -31.4% |
| Q2 2018 | $16,702,000 | -12.7% | 2,724,663 | +3.8% | 2.63% | -11.8% |
| Q1 2018 | $19,134,000 | -10.0% | 2,624,663 | +1.3% | 2.98% | -14.2% |
| Q4 2017 | $21,252,000 | -43.3% | 2,591,721 | -27.4% | 3.47% | -37.3% |
| Q3 2017 | $37,465,000 | -17.8% | 3,568,122 | -13.7% | 5.54% | +0.1% |
| Q2 2017 | $45,592,000 | +7.2% | 4,133,464 | -5.9% | 5.54% | +7.5% |
| Q1 2017 | $42,538,000 | – | 4,394,464 | – | 5.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 1,625,000 | $12,269,000 | 3.04% |
| GENDELL JEFFREY L | 1,146,764 | $8,658,000 | 1.11% |
| Broadfin Capital, LLC | 1,029,012 | $7,769,000 | 1.04% |
| RTW INVESTMENTS, LP | 3,401,434 | $25,681,000 | 0.97% |
| BRANDES INVESTMENT PARTNERS, LP | 3,651,948 | $27,571,000 | 0.66% |
| Aristides Capital LLC | 71,520 | $540,000 | 0.42% |
| Tekla Capital Management LLC | 814,588 | $6,150,000 | 0.23% |
| INVESTORS ASSET MANAGEMENT OF GEORGIA INC /GA/ /ADV | 36,100 | $273,000 | 0.17% |
| Leap Investments LP | 43,481 | $328,000 | 0.15% |
| Brown Capital Management | 1,829,886 | $13,816,000 | 0.13% |